Program


Workshop: Demystifying lipids – Understanding why lower is better

May 24, 2024 from 9:40am MDT to 10:30am MDT

One of the main goals following an acute coronary syndrome (ACS) event, is to prevent recurrent cardiovascular (CV) events, thus reducing CV morbidity and mortality. Elevated LDL-C levels are an important modifiable risk factor that contributes to the pathogenesis of atherosclerotic cardiovascular disease (ASCVD). The initial 2–3-month period following an ACS admission is a vulnerable period for recurrent CV events. Early initiation of moderate to high intensity statin therapy is recommended to reduce recurrent CV events. The 2021 Canadian Cardiovascular Society (CCS) lipid guidelines recommended LDL-C <1.8mmol/L as the threshold for which intensification of lipid-lowering therapy should occur. There is robust evidence that adding non-statin therapies such as ezetimibe and/or PCSK9 inhibitors can further aid in LDL-C reduction. Unfortunately, 15 out of 100 patients report statin-related muscle symptoms, but research shows only one case is directly related to statin use. Evidence reports that up to 50% of patients stop their statin therapy within the first year of treatment. The purpose of this workshop is to review the 2021 CCS lipid lowering guidelines for secondary prevention, discuss the gaps and barriers in lipid management post-ACS, and the opportunities nurses have in improving evidenced-based cardiovascular risk reduction with education on why ‘lower is better’. The presenters will review a case study with practical tips on managing statin intolerance, and how we as nurses can educate our patients on the importance of adherence to their prescribed lipid lowering therapy to reduce recurrent CV risk.

Speakers / Panelists